Mathieu Morand: Insights from World Cancer Series on Healthcare Innovation and Access Misalignment

At a World Cancer Series panel last week, a venture capitalist made an observation that Mathieu Morand — Director of the C/Can Accelerator Hub at City Cancer Challenge — had been sitting with for years: the financial mechanics of healthcare venture capital are structurally misaligned with what public health systems actually need. For our readers tracking the longevity space, the point is not abstract. The same incentive architecture is shaping where cellular-rejuvenation platforms, advanced biomarkers, and anti-aging therapeutics are being built, priced, and distributed right now.

Where the misalignment lives

Morand, who moved from venture capital into global health, describes a specific mechanism rather than a vague critique. Private capital returns in healthcare come from premium markets and well-insured population segments. Innovation, in practice, becomes available to the small fraction of patients who can pay out of pocket. The disease and aging burden carried by the rest of the population rarely produces the multiples a fund requires. The pipeline is, by design, optimized for the affluent end of the demand curve.

The 8-year clock

One concrete datapoint from Morand's account is worth holding onto: the industry typically structures for ROI inside an 8-year window. That horizon is too compressed to build, validate, and scale interventions for the populations with the largest unmet need. We observe the downstream effect in the longevity category with some consistency — emerging protocols reach first-tier urban markets under the same pricing logic that oncology innovation has followed for a decade. Mechanistic promise, in other words, does not translate into population access on its own.

What we are tracking

Morand's open question — who absorbs the access function when the investment model is not built to carry it — is the right one to monitor. He lists plausible candidates: the firms that buy out innovative businesses, regulators, individual entrepreneurs, underfunded NGOs, and international agencies. Each has partial reach. None currently combines the mandate, the balance sheet, and the patience to close the gap alone. For longevity specifically, the relevant variable is whether outcomes-based contracts, public-private consortia, or sovereign health funds can shift the distribution curve, or whether the field simply inherits the same access pattern oncology is now being criticized for. The existing evidence is consistent with inheritance. We will note credible counterexamples as they surface.